Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cesitrex
- Development stage
- Unknown
- Lead developer
- Perspective Therapeutics
- Administration
- Local Implantation Into Surgical Resection Cavity
01
Overview
Cesitrex is a radionuclide brachytherapy source component intended for use with the GliaSite Radiation Therapy System (RTS), a device-based intracavitary brachytherapy platform for delivering localized radiation to the resection cavity after brain tumor surgery. As described in its FDA 510(k) submission, Cesitrex functions as the radionuclide source/applicator that is placed within the GliaSite balloon catheter to provide controlled, site-specific irradiation of residual tumor cells in the brain, improving local control while limiting dose to surrounding healthy tissue.[4] It is regulated as a radionuclide brachytherapy source rather than as a conventional pharmaceutical.
Beyond the preview
Go deeper on Cesitrex.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cesitrex.